

1600

RAW SEQUENCE LISTING

DATE: 05/30/2003

PATENT APPLICATION: US/09/724,953

TIME: 10:53:06

Input Set : A:\015270-005913US.APP

Output Set: N:\CRF4\05302003\I724953.raw

```
3 <110> APPLICANT: Schenk, Dale B.
              Elan Pharmaceuticals
      6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Diseases
      8 <130> FILE REFERENCE: 015270-005913US
     10 <140> CURRENT APPLICATION NUMBER: US 09/724,953
     11 <141> CURRENT FILING DATE: 2000-11-28
     13 <150> PRIOR APPLICATION NUMBER: US 09/585,817
     14 <151> PRIOR FILING DATE: 2000-06-01
     16 <150> PRIOR APPLICATION NUMBER: US 60/137,010
     17 <151> PRIOR FILING DATE: 1999-06-01
     19 <160> NUMBER OF SEQ ID NOS: 34
     21 <170> SOFTWARE: PatentIn Ver. 2.1
                                                     ENTERED
     23 <21-0> SEQ ID NO: 1
     24 <211> LENGTH: 13
     25 <212> TYPE: PRT
     26 <213> ORGANISM: Artificial Sequence
     28 <220> FEATURE:
     29 <223> OTHER INFORMATION: Description of Artificial Sequence:influenza
              hemagglutinin HA 307-319 universal T-cell epitope
     32 <400> SEQUENCE: 1
     33 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
     37 <210> SEQ ID NO: 2
     38 <211> LENGTH: 13
     39 <212> TYPE: PRT
     40 <213> ORGANISM: Artificial Sequence
     42 <220> FEATURE:
     43 <223> OTHER INFORMATION: Description of Artificial Sequence: PADRE universal
             T-cell epitope
     46 <220> FEATURE:
     47 <221> NAME/KEY: MOD_RES
     48 <222> LOCATION: (3)
     49 <223> OTHER INFORMATION: Xaa = any amino acid
     51 <400> SEQUENCE: 2
W--> 52 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
     53 1
     56 <210> SEQ ID NO: 3
     57 <211> LENGTH: 16
     58 <212> TYPE: PRT
     59 <213> ORGANISM: Artificial Sequence
     61 <220> FEATURE:
     62 <223> OTHER INFORMATION: Description of Artificial Sequence:malaria CS T3
     63
```

epitope universal T-cell epitope

DATE: 05/30/2003

TIME: 10:53:06

Input Set: A:\015270-005913US.APP Output Set: N:\CRF4\05302003\I724953.raw 65 <400> SEQUENCE: 3 66 Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val 70 <210> SEQ ID NO: 4 71 <211> LENGTH: 10 72 <212> TYPE: PRT 73 <213> ORGANISM: Artificial Sequence 75 <220> FEATURE: 76 <223> OTHER INFORMATION: Description of Artificial Sequence: Hepatitis B surface antigen HBsAg 19-28 universal T-cell 78 epitope 80 <400> SEQUENCE: 4 81 Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile 1 85 <210> SEQ ID NO: 5 86 <211> LENGTH: 19 87 <212> TYPE: PRT 88 <213> ORGANISM: Artificial Sequence 90 <220> FEATURE: 91 <223> OTHER INFORMATION: Description of Artificial Sequence: heat shock protein 65 hsp65 153-171 universal T-cell epitope 94 <40.0> SEQUENCE: 5 95 Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly 96 1 98 Asn Glu Gly 102 <210> SEQ ID NO: 6 103 <211> LENGTH: 14 104 <212> TYPE: PRT 105 <213> ORGANISM: Artificial Sequence 107 <220> FEATURE: 108 <223> OTHER INFORMATION: Description of Artificial Sequence:bacillus Calmette-Guerin universal T-cell epitope 111 <400> SEQUENCE: 6 112 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu 113 1 1.0 116 <210> SEQ ID NO: 7 117 <211> LENGTH: 15 118 <212> TYPE: PRT 119 <213> ORGANISM: Artificial Sequence 121 <220> FEATURE: 122 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid TT 830-844 universal T-cell epitope 125 <400> SEQUENCE: 7 126 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 127 1 10 130 <210> SEQ ID NO: 8 131 <211> LENGTH: 21 132 <212> TYPE: PRT 133 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,953

RAW SEQUENCE LISTING DATE: 05/30/2003 PATENT APPLICATION: US/09/724,953 TIME: 10:53:06

Input Set : A:\015270-005913US.APP
Output Set: N:\CRF4\05302003\I724953.raw

```
135 <220> FEATURE:
136 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid
          TT 947-967 universal T-cell epitope
139 <400> SEQUENCE: 8
140 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
                                         10
143 Ala Ser His Leu Glu
144
                 20
147 <210> SEQ ID NO: 9
148 <211> LENGTH: 16
149 <212> TYPE: PRT
150 <213> ORGANISM: Artificial Sequence
152 <220> FEATURE:
153 <223> OTHER INFORMATION: Description of Artificial Sequence: HIV gp120 T1
154
          universal T-cell epitope
156 <400> SEQUENCE: 9
157 Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
                                          10
161 <210> SEQ ID NO: 10
162 <211> LENGTH: 22
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial Sequence
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Description of Artificial Sequence: AN90549 (Abeta
          1-7/tetanus toxoid 830-844 in a MAP4
          configuration)
171 <400> SEQUENCE: 10
172 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
175 Ile Gly Ile Thr Glu Leu
176
                 20
179 <210> SEQ ID NO: 11
180 <211> LENGTH: 28
181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: Description of Artificial Sequence: AN90550 (Abeta
          1-7/tetanus toxoid 947-967 in a MAP4
187
          configuration)
189 <400> SEQUENCE: 11
190 Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp
191
      1
                                          10
193 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
                 20
                                     25
197 <210> SEQ ID NO: 12
198 <211> LENGTH: 43
199 <212> TYPE: PRT
200 <213> ORGANISM: Artificial Sequence
202 <220> FEATURE:
```

DATE: 05/30/2003

TIME: 10:53:06

Input Set: A:\015270-005913US.APP Output Set: N:\CRF4\05302003\I724953.raw 203 <223> OTHER INFORMATION: Description of Artificial Sequence: AN 90542 (Abeta 1-7/tetanus toxoid 830-844 + 947-967 in a linear 204 configuration) 207 <400> SEQUENCE: 12 208 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe 5 10 211 Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 212 20 25 214 Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 218 <210> SEQ ID NO: 13 219 <211> LENGTH: 22 220 <212> TYPE: PRT 221 <213> ORGANISM: Artificial Sequence 223 <220> FEATURE: 224 <223> OTHER INFORMATION: Description of Artificial Sequence: AN 90576 (Abeta 225 3-9/tetanus toxoid 830-844 in a MAP4 configuration) 228 <400> SEQUENCE: 13 229 Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe 232 Ile Gly Ile Thr Glu Leu 233 20 236 <210> SEQ ID NO: 14 237 <211> LENGTH: 20 238 <212> TYPE: PRT 239 <213> ORGANISM: Artificial Sequence 241 <220> FEATURE: 242 <223> OTHER INFORMATION: Description of Artificial Sequence: AN90562 (Abeta 243 1-7/peptide on linear conformmation) 245 <220> FEATURE: 246 <221> NAME/KEY: MOD RES 247 <222> LOCATION: (3) 248 <223> OTHER INFORMATION: Xaa = any amino acid 250 <400> SEQUENCE: 14 W--> 251 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu 252 1 10 254 Phe Arg His Asp 255 258 <210> SEQ ID NO: 15 259 <211> LENGTH: 34 260 <212> TYPE: PRT 261 <213> ORGANISM: Artificial Sequence 263 <220> FEATURE: 264 <223> OTHER INFORMATION: Description of Artificial Sequence: AN90543 (Abeta 1-7 X 3/peptide in linear conformation) 267 <220> FEATURE: 268 <221> NAME/KEY: MOD RES 269 <222> LOCATION: (24)

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003

```
PATENT APPLICATION: US/09/724,953
                                                              TIME: 10:53:06
                     Input Set: A:\015270-005913US.APP
                     Output Set: N:\CRF4\05302003\I724953.raw
     270 <223> OTHER INFORMATION: Xaa = any amino acid
     272 <400> SEQUENCE: 15
     273 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala
                                               10
W--> 276 Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala
     277
                      20
     279 Ala Ala
     283 <210> SEQ ID NO: 16
     284 <211> LENGTH: 34
     285 <212> TYPE: PRT
     286 <213> ORGANISM: Artificial Sequence
     288 <220> FEATURE:
     289 <223> OTHER INFORMATION: Description of Artificial Sequence: fusion protein
               with Abeta immunogenic epitope
     292 <220> FEATURE:
     293 <221> NAME/KEY: MOD RES
     294 <222> LOCATION: (3)
     295 <223> OTHER INFORMATION: Xaa = any amino acid
     297 <400> SEQUENCE: 16
W--> 298 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu
     299
     301 Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg
     302
                      20
                                           2.5
     304 His Asp
     308 <210> SEQ ID NO: 17
     309 <211> LENGTH: 20
     310 <212> TYPE: PRT
     311 <213> ORGANISM: Artificial Sequence
     313 <220> FEATURE:
     314 <223> OTHER INFORMATION: Description of Artificial Sequence: fusion protein
     315
               with Abeta immunogenic epitope
     317 <220> FEATURE:
     318 <221> NAME/KEY: MOD RES
     319 <222> LOCATION: (10)
     320 <223> OTHER INFORMATION: Xaa = any amino acid
     322 <400> SEQUENCE: 17
W--> 323 Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu
     324
     326 Lys Ala Ala Ala
     330 <210> SEQ ID NO: 18
     331 <211> LENGTH: 24
     332 <212> TYPE: PRT
     333 <213> ORGANISM: Artificial Sequence
     335 <220> FEATURE:
     336 <223> OTHER INFORMATION: Description of Artificial Sequence: fusion protein
               with Abeta immunogenic epitope
     339 <400> SEQUENCE: 18
     340 Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His
```

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 05/30/2003 PATENT APPLICATION: US/09/724,953 TIME: 10:53:07

Input Set : A:\015270-005913US.APP

Output Set: N:\CRF4\05302003\I724953.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos/3 Seq#:14; Xaa Pos/3 Seq#:15; Xaa Pos./24 Seq#:16; Xaa Pos. 3 Seq#:17; Xaa Pos. 10 Seq#:32; Xaa Pos. 2 Seq#:33; Xaa Pos. 1